Vigil Neuroscience Net Worth
Vigil Neuroscience Net Worth Breakdown | VIGL |
Vigil Neuroscience Net Worth Analysis
Vigil Neuroscience's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Vigil Neuroscience's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Vigil Neuroscience's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Vigil Neuroscience's net worth analysis. One common approach is to calculate Vigil Neuroscience's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Vigil Neuroscience's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Vigil Neuroscience's net worth. This approach calculates the present value of Vigil Neuroscience's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Vigil Neuroscience's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Vigil Neuroscience's net worth. This involves comparing Vigil Neuroscience's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Vigil Neuroscience's net worth relative to its peers.
Enterprise Value |
|
To determine if Vigil Neuroscience is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Vigil Neuroscience's net worth research are outlined below:
| Vigil Neuroscience had very high historical volatility over the last 90 days | |
| Vigil Neuroscience has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (82.64 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Vigil Neuroscience currently holds about 148.91 M in cash with (70.36 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.27, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Vigil Neuroscience has a poor financial position based on the latest SEC disclosures | |
| Over 78.0% of the company outstanding shares are owned by institutional investors | |
| Latest headline from stockhead.com.au: Health Check With its last patient treated, Opthea eyes pending results of do-or-die trial |
Vigil Neuroscience uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Vigil Neuroscience. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Vigil Neuroscience's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 19th of March 2024 Upcoming Quarterly Report | View | |
| 8th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 19th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Vigil Neuroscience's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Vigil Neuroscience is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Vigil Neuroscience backward and forwards among themselves. Vigil Neuroscience's institutional investor refers to the entity that pools money to purchase Vigil Neuroscience's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Woodline Partners Lp | 2024-12-31 | 488.8 K | Rock Springs Capital Management Lp | 2024-12-31 | 472 K | Orbimed Advisors, Llc | 2024-09-30 | 448.9 K | Blackrock Inc | 2024-12-31 | 420.7 K | Renaissance Technologies Corp | 2024-12-31 | 367.3 K | Millennium Management Llc | 2024-12-31 | 343.8 K | Blair William & Co | 2024-12-31 | 323.9 K | Arrowmark Colorado Holdings, Llc (arrowmark Partners) | 2024-12-31 | 289.5 K | Marshall Wace Asset Management Ltd | 2024-12-31 | 266.9 K | Northpond Ventures, Llc | 2024-09-30 | 4.2 M | Siren, L.l.c. | 2024-12-31 | 2 M |
Follow Vigil Neuroscience's market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 109.15 M.Market Cap |
|
Project Vigil Neuroscience's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.53) | (0.55) | |
| Return On Capital Employed | (0.79) | (0.83) | |
| Return On Assets | (0.53) | (0.55) | |
| Return On Equity | (0.82) | (0.78) |
When accessing Vigil Neuroscience's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Vigil Neuroscience's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Vigil Neuroscience's profitability and make more informed investment decisions.
Evaluate Vigil Neuroscience's management efficiency
Vigil Neuroscience has return on total asset (ROA) of (0.3806) % which means that it has lost $0.3806 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7362) %, meaning that it created substantial loss on money invested by shareholders. Vigil Neuroscience's management efficiency ratios could be used to measure how well Vigil Neuroscience manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return On Tangible Assets is estimated to slide to -0.55. The value of Return On Capital Employed is expected to slide to -0.83. At this time, Vigil Neuroscience's Net Tangible Assets are quite stable compared to the past year. Non Current Assets Total is expected to rise to about 22.9 M this year, although the value of Other Current Assets will most likely fall to about 2.7 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 2.70 | 2.84 | |
| Tangible Book Value Per Share | 2.70 | 2.84 | |
| Enterprise Value Over EBITDA | (0.94) | (0.99) | |
| Price Book Value Ratio | 1.01 | 1.06 | |
| Enterprise Value Multiple | (0.94) | (0.99) | |
| Price Fair Value | 1.01 | 1.06 | |
| Enterprise Value | 106.6 M | 155.3 M |
At Vigil Neuroscience, effective management practices are pivotal to sustaining long-term profitability. We delve into financial metrics and market conditions to provide a comprehensive analysis of the stock's prospects.
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Vigil Neuroscience insiders, such as employees or executives, is commonly permitted as long as it does not rely on Vigil Neuroscience's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Vigil Neuroscience insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Vigil Neuroscience Corporate Filings
| 12th of February 2025 Other Reports | ViewVerify | |
8K | 23rd of January 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 19th of December 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
Vigil Neuroscience Earnings per Share Projection vs Actual
Vigil Neuroscience Corporate Management
| CPA CPA | Chief Officer | Profile | |
| Spyridon MD | Chief Officer | Profile | |
| Weeteck Yeo | Senior Operations | Profile | |
| Jessica PMP | Senior Management | Profile | |
| Mr DABT | Senior Development | Profile | |
| Christopher JD | General Secretary | Profile |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Vigil Neuroscience. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. For more information on how to buy Vigil Stock please use our How to buy in Vigil Stock guide.You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Vigil Neuroscience. If investors know Vigil will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Vigil Neuroscience listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Vigil Neuroscience is measured differently than its book value, which is the value of Vigil that is recorded on the company's balance sheet. Investors also form their own opinion of Vigil Neuroscience's value that differs from its market value or its book value, called intrinsic value, which is Vigil Neuroscience's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Vigil Neuroscience's market value can be influenced by many factors that don't directly affect Vigil Neuroscience's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Vigil Neuroscience's value and its price as these two are different measures arrived at by different means. Investors typically determine if Vigil Neuroscience is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Vigil Neuroscience's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.